The Japanese Journal of Antibiotics
Online ISSN : 2186-5477
Print ISSN : 0368-2781
ISSN-L : 0368-2781
BACTERIA ISOLATED FROM INTRAABDOMINAL INFECTION AND THEIR SUSCEPTIBILITIES TO ANTIMICROBIAL AGENTS
NAGAO SHINAGAWAAKIRA MIZUNOKENJI MASHITAJIRO YURASYU ISHIKAWAKOICHI HIRATARYUICHI DENNOMITSUHIRO MUKAIYAKYUYA ISHIBIKINAOKI AIKAWAKIYOTSUGU TAKUMATAKASHI TANAKASHIGETOMI IWAIHIDEO TANAKAHIROAKI KINOSHITAKEN MORIMOTOMIKIO FUJIMOTOHIROSHI TANIMURAHIRONOBU OHNISHIKOHEI NOGUCHISHIZUMA MIZOBATAYOSHIYA UMEMOTOKUNZO ORITAFUMIYUKI INOUESADAYOSHI FUCHIMOTOHIDEYUKI KIMURAEIJI KONAGAYUUICHIRO MATSUURATAKASHI KODAMATAKASHI YOKOYAMAEIZO HIYAMASEIYO IKEDAHIROSHI YAMAMOTOYOHICHI YASUNAMIKOICHI DEGUCHI
Author information
JOURNAL FREE ACCESS

1994 Volume 47 Issue 10 Pages 1329-1343

Details
Abstract
Bacteria isolated from intraabdominal infections during the period from July 1982 to June 1993 were investigated with regard to their classifications according to a joint research by 9 university hospitals in Japan. The following results were obtained.
1. A total of 971 strains were isolated from 684 out of 597 patients with peritonitis, and 287 strains out of 971 were isolated from postoperative peritonitis.
2. The most predominant organism isolated from patients with acute peritonitis was Escherichia coli (28%), followed by Bacteroides fragilis group (17%), Gram-positive anaerobic cocci (16%), Enterococcus spp.(9%) and Klebsiella spp.(8%).
3. Against E. coli, cefmenoxime, cefuzonam, cefozopran, aztreonam and carumonam showed MIC50 less than 0.05μ/ml. Against B. fragilis group, erythromycin, clindamycin, imipenem, lincomycin and latamoxef showed MIC50 less than 0.78μ/ml.
4. The most predominant organism isolated from patients with postoperative peritonitis was Enterococcus spp.(20%) and followed by Pseudomonas spp.(14%), and Staphylococcus spp.(13%), E. coli (9%), Enterobacter spp.(8%) and Klebsiella spp.(8%).
We suggest that cefazolin, cefmetazole, flomoxef, cefmenoxime, cefuzonam and latamoxef are the first choice agents in empiric therapy for the treatment of acute peritonitis.
Content from these authors
© Japan Antibiotics Research Association
Previous article Next article
feedback
Top